Healios KK Ord Shs HLOSF

Healthcare Biotechnology

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.

PINL:HLOSF - Post by User

Healios KK Ord Shs

<< Previous

Bullboard Posts

Next >>

Post by sweenbyon Oct 19, 2010 10:57pm

238 Views

Post# 17585617

Halo closes

Halo Resources closes $450,000 private placement

2010-10-19 22:21 ET - News Release

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Mr. Marc Cernovitch reports

HALO COMPLETES $450,000 FINANCING

Halo Resources Ltd. has completed its financing announced in Stockwatch on Sept. 29, 2010, as amended in Stockwatch on Oct. 1, 2010, by issuing 1.8 million units at a price of 25 cents per unit for total gross proceeds of $450,000. Each unit comprised one common share of the company and one common share purchase warrant. Each warrant is exercisable to acquire one additional common share of the company for two years at a price of 35 cents per share. Finders' fees totalling $7,200 cash and 21,600 finder warrants were paid on a portion of the private placement. The finder warrants have the same terms as the private placement warrants.